TGFB1 and renal fibrosis: DPP4 inhibitors (such as linagliptin and DA-1229) suppressed TGF-β/Smad-mediated renal fibrosis [34, 35] and prevented podocyte damage without lowering the blood glucose in diabetic condition [24, 36], [37].